The effect of Hyoscin on the cervix of non-pregnant married women before curettage.
Phase 2
- Conditions
- terine cervical firmness.Diseases of the genitourinary system
- Registration Number
- IRCT2015121312190N5
- Lead Sponsor
- Vice chancellor for research, Shahid Beheshti University of Medical Science.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Inclusion Criteria: women with gynecological diseases who were scheduled for curettage; Good general health; Want to participate in the study after it is explained; Increased endometrial thickness in sonography evaluation or irregular endometrial echo in sonographic view; Uterine cervical firmness in examination.
Exclusion Criteria
abundant vaginal bleeding; use of hormone replacement therapy lately; history of hypersensitivity to or contraindication of the Hyoscin usage.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method terine cervical dilatation. Timepoint: at the beginning of the study , then 2 hours after the second dose of the investigating drug. Method of measurement: Budgie.;Uterine cervical consistancy. Timepoint: at the beginning of the study , then 2 hours after the second dose of the investigating drug. Method of measurement: passing number 2 Currett through uterine cervix and see its resistance.
- Secondary Outcome Measures
Name Time Method Tackykardia. Timepoint: 2 hours after the second dose of the drug (at the beginning of the procedure). Method of measurement: Questionnaire.;Uterine perforation. Timepoint: when the device passed through the cervical canal. Method of measurement: Examination.;Tearing of the uterine cervix. Timepoint: when the device passed through the cervical canal. Method of measurement: Examination.;Mouth dryness. Timepoint: 2 hours after the second dose of the drug (at the beginning of the procedure). Method of measurement: Questionnaire.;Nausea and vomitting. Timepoint: 2 hours after the second dose of the drug (at the beginning of the procedure). Method of measurement: Questionnaire.